SUNFLOWER(SZ:300111) Xin Lang Cai Jing·2026-01-15 01:59Core Viewpoint - The company, Zhejiang Sunflower Health Technology Co., Ltd., has received a notice from the China Securities Regulatory Commission (CSRC) regarding an investigation into alleged violations of information disclosure laws, leading to a formal case being opened against the company [1][2][3]. Group 1: Investigation Details - The CSRC's investigation is prompted by market doubts regarding the actual production capacity and business model of the company's restructuring targets, which are suspected of containing misleading statements [3][4]. - The Zhejiang Securities Regulatory Bureau has initiated a verification process and will handle the case based on a comprehensive investigation to maintain order in the mergers and acquisitions market [3]. Group 2: Termination of Restructuring Plans - Concurrently, the company announced the termination of its plans to issue shares and pay cash for the acquisition of 100% of Zhangzhou Xipu Material Technology Co., Ltd. and 40% of Zhejiang Beid Pharmaceutical Co., Ltd., as well as to raise supporting funds through a share issuance [2][4]. - The termination is due to the company's non-compliance with conditions for issuing shares to purchase assets following the receipt of the CSRC's notice [4]. Group 3: Investor Implications - Legal experts indicate that investors who purchased shares between September 22, 2025, and January 14, 2026, and sold or held them after January 15, 2026, may be eligible for compensation due to the company's situation [2][4].